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Objectives. We studied the hypothesis that in the absence of
vascular pathology, coronary artery vasospasm occurs as a result
of local regions of vascular muscle hyperreactivity. We aimed to
explore the basis for a functional etiology of those vasospasms not
explained on a structural basis.
Background. Ovariectomized rhesus monkeys (Macaca mulatta)
without injury or significant vascular disease were stimulated with
platelet release products, and angiograms were compared with
those from vasospasms induced in human patients.
Methods. We used intracoronary (IC) injections of serotonin,
thromboxane A2 (U46619), endothelin 1 or angiotensin II in
concentrations 3 to 10 times that which reduced coronary artery
diameter by 50%.
Results. Although no agent alone caused vasospasm, the com-
bination of pathophysiologic concentrations of serotonin and the
stable thromboxane A2 mimetic, U46619, injected through an IC
catheter, synergistically caused coronary vasospasm on the second
or third challenge in five of seven monkeys. These drug-induced
vasospasms were similar to vasospasms induced by mechanical
injury followed by serotonin, and to those stimulated in human IC
diagnostic tests, as judged by onset, appearance, kinetics and
vasodilator reversal.
Conclusions. These studies in ovariectomized monkeys revealed
that coronary vasospasm can be stimulated without preexisting
vascular pathology, endothelial denudation or injury. Reproduc-
ible vasospasm of primate coronary arteries in response to these
two endogenous pathophysiologic vasoconstrictors, which are
thought to be precipitating stimuli in the etiology of vasospasm,
suggests that structure-independent epicardial vasospasm can be
an important element in serious cardiac ischemic events, partic-
ularly the focal, persistent vasospasms that occur without plaques
or injury.
(J Am Coll Cardiol 1997;29:671–80)
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Coronary vasospasm is a phenomenon identified by focal
constrictions followed by downstream dilations in a character-
istic hourglass-shaped pattern, with an underlying mechanism
that is only partially explained (1). The focal constrictions in
this signature pattern imply local vascular muscle hyperreac-
tivity and persistent contraction as a definitive feature of
vasospasm (1–6). Thromboxane A2 and serotonin have been
suggested as the initiating stimulus (7–9), a concept that is
supported by animal and human studies (10). When injury or
plaque rupture occurs, additional mediators include thrombin,
adenosine diphosphate, free radicals of oxygen and platelet-
activating factor, which would predispose toward initiation of
vasospasm; furthermore, injury would simultaneously reduce
potent endothelial relaxant factors (e.g., endothelial-dependent
relaxant factor, prostacyclin and tissue-type plasminogen acti-
vator) (10). Although platelet release products seem to be
major factors in vasospasm (11,12), it is not clear that these
substances can produce vasospasm in the absence of plaques or
injury.
Although structural occlusion explains a major fraction of
fatal ischemic events, the vasospasm phenomenon can be
localized and episodic and is not always correlated with
atherosclerotic plaques (1,2,13,14). Although plaque rupture is
believed to be the initiating event in most cases of vasospasm
and acute myocardial infarction, locally released vasoconstric-
tors are obligatory to an explanation of the segmental occlu-
sion pattern and probably initiate vasospasm, particularly
where plaques are either stable or absent.
Variant angina has been hypothetically explained by func-
tional, putatively drug-induced vasospasms (1,2,6,15–17).
Several agents, including serotonin, thromboxane A2
(TxA2), endothelin (ET1) and angiotensin II (AII) have been
hypothesized (2,10,14,18) as vasoconstrictors responsible for
vasospasm.
In human patients, coronary plaques are common and
sometimes not correlated with vasospasm, which suggests that
functional changes are a critical factor (13,14). However, the
widespread occurrence of coronary atherosclerosis is itself a
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complication for the analysis in humans (14,15,18,19). Hyper-
reactivity to vasoconstrictors has been shown (20) to precede
atherosclerotic changes, and the decline in hyperreactivity to
precede structural regression, in a primate model of diet-
induced atherosclerosis. Thus, investigation of coronary hyper-
reactivity itself is greatly in need of additional study. Similar-
ities of cardiovascular reflexes (21) and receptors (22) in
nonhuman primates to those in humans and productive studies
of atherosclerosis and coronary vasospasm in monkeys (20,23–
25) led us to explore provoking coronary vasospasm in rhesus
monkeys without coronary plaques or injury. This series of
experiments explored whether a single agent or combination of
vasoconstrictors together could stimulate the characteristic
hourglass form of coronary vasospasm in the absence of
injuries or plaques.
Our specific hypothesis was as follows. In the absence of
protective factors (e.g., in the state of hypoestrogenism) and
without arterial wall pathology or injury, localized regions of
abnormal hyperreactivity in response to platelet vasoconstric-
tor products occur in coronary arteries; these foci of hyperre-
activity can result in responses to platelet-released serotonin in
combination with TxA2 that include exaggerated, persistent
contractions that fail to be reversed by normal inactivation
processes of vascular muscle cell (VMC) and are sufficient to
explain vasospasms. An important corollary is that neither
structural occlusion nor injury is required for vasospasm,
although plaque rupture and artery injury would be important
components where they existed. A preliminary report of our
results was presented previously (26).
Methods
Vasospasm definition. It is essential to differentiate 1)
physiologic, autoregulatory constrictions that allow for a range
of coronary blood flows versus 2) pathologic prolonged con-
strictions that result in ischemia and injury to the myocardium
(2,6,27). Therefore, we define coronary vasospasm as epicardial
coronary artery constriction to ,25% of control diameter in
focal areas with adjacent downstream dilation, with the hour-
glass pattern thus formed persisting for .5 min.
The characteristic hourglass appearance (see pp. 676 and
677) was the ultimate criterion used to define vasospasm.
Reactivity-based vasospasm is implied by enhanced responses
to pharmacologic stimuli in the absence of predisposing struc-
tural factors and thus we hypothesize might be explained by
local exaggerated constrictions to stimuli.
Animals. We studied 10 adult rhesus monkeys (Macaca
mulatta) 7 to 19 years old (average 13.4) in the main protocols
described below and 5 additional monkeys in preliminary
experiments. For the 10 main study animals, we used 1 male
(14 years old) weighing 10.3 kg and 9 ovariectomized (ovx)
female monkeys weighing 5.3 to 8.2 kg (average 6.2), none of
which had been exposed to high cholesterol diets and which
were later verified (see Results) to lack evidence of cardiovas-
cular disease. Ovx rhesus monkeys were entered into the study
no less than 3 months after ovariectomy.
Catheterization studies. Angiography at the Dotter Insti-
tute, after overnight fasting, began with preanesthesia with
ketamine (10 mg/kg body weight intramuscular), intubation
with an endotracheal tube and a light surgical plane of
anesthesia with isoflurane (induced at 1.5% to 3%, maintained
at 0.75% to 1.25%), vaporized with 33% nitrous oxide and 67%
oxygen. Bilateral femoral intraarterial catheters allowed for
coronary catheterization and continuous recording of systemic
arterial blood pressure and heart rate, which were maintained
close to the initial anesthetic value for each monkey. Intrave-
nous heparin (1,000 U) was injected, and up to 120 ml of
lactated Ringer’s solution and 0 to 10 ml of dextran solution
were used (as needed) to maintain diastolic blood pressure
$60 mm Hg. A heating pad assisted in maintenance of a body
temperature decrease #28C of preanesthesia body tempera-
ture (monitored by rectal thermometer). An electrocardio-
gram (ECG) recorded on a Gould eight-channel recorder,
cutaneous arterial oxygen saturation, respiratory rate and
end-tidal CO2 were also monitored.
Entire experiments were recorded on videotape (with epi-
sodic fluoroscopic imaging and continuous voice annotation)
to permit computerized quantitative coronary angiography.
Protocol 1 (Table 1) evolved from a series of pilot studies in
five additional monkeys in which we tested different combina-
tions and doses of the four vasoconstrictors serotonin, TxA2,
ET1 and AII. Vasoconstrictor concentrations were incre-
mented in log units because of the log-normal distribution of
sensitivities in blood vessels (28). Because vasospasms were
only observed in ovx monkeys and in response to serotonin and
TxA2 in combination, we focused on this combination.
Placement of the 3F catheter (except as noted later) was
adjusted to provide sufficient filling with radioopaque contrast
medium, limited reflux and isolation of a branch of the
coronary arterial tree. Usually the left anterior descending
coronary artery (LAD) was chosen, but the left circumflex (in
two cases) or right coronary artery (in one case) was used
instead, based on optimal placement and to avoid occlusion of
blood flow. After adjustment of the camera angle to optimally
image the coronary vascular tree, warm (35 to 388C) 1- to 2-ml
boluses of Hexabrix (Mallinckrodt) radioopaque contrast me-
dia were injected rapidly by hand to fill optimally. Fluoroscopic
images were recorded on film using a Toshiba CAS-CP
Abbreviations and Acronyms
AII 5 angiotensin II
ACh 5 acetylcholine
dP/dt 5 rate of increase in left ventricular pressure
EC50 5 effective concentration for 50% of a specified response
ET1 5 endothelin-1
IC 5 intracoronary
LAD 5 left anterior descending coronary artery
ovx 5 ovariectomized
TxA2 5 thromboxane A2
VMC 5 vascular muscle cell
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Angiorex system with fluoroscopic C-arm, developed immedi-
ately and evaluated for suitability of subsequent analysis.
Every injection of drugs was made by intracoronary (IC)
route, with a slow, constant flow of 1 ml over 3061 s. The time
between drug injections was typically 7 to 10 min, and no less
than 4 min, with pressures and heart rates allowed to return to
#15% change from baseline before the next injection. All
concentrations given in the Methods section are syringe con-
centrations (uncorrected for dilution by coronary blood flow)
to exactly describe the procedure. (The effective concentra-
tions in the blood are presented in the Results section and in
Table 3, as explained later.)
The drug-induced protocol, listed in Table 1, was the
sequence of injections followed for the seven ovx monkeys.
Step 1 established control coronary diameters; step 2 was slow
IC injection of 1 ml of 100 nmol/liter of acetylcholine (ACh),
a total of 0.018 mg, to validate endothelial function, as ob-
served by vasodilation of large coronary arteries. Step 3 was IC
injection of 1 ml of 1 mmol/liter (a total of 0.18 mg) ACh. The
higher ACh dose is about 500 times less than the 100 mg used
for provoking vasospasm in susceptible patients (19,29).
The fourth step in protocol 1 (Table 1) was 1 ml of 100
mmol/liter serotonin (a total of 17.6 mg), a vasodilator dose
that provided an additional test of endothelial dilator function.
The fifth step was to inject 1 mmol/liter serotonin to directly
vasoconstrict VMC. The sixth and seventh steps were injection
of 100 nmol/liter U46619 (0.035 mg) and 1 mmol/liter U46619.
The eighth to tenth steps, which were 1-ml injections of 100
mmol/liter serotonin and 1 mmol/liter U46619 combined, were
the critical steps. These concentrations of serotonin and TxA2
injected in three repeated challenges provoked drug-induced
vasospasm. Sensitivity was determined by response to the first,
second or third stimulus, allowing at least a 7-min delay from
one injection to the next. For three of these seven ovx
monkeys, 1-nM ET1 (alone and plus serotonin) and 1-mmol/
liter AII (alone and plus serotonin) steps were administered
between steps 10 and 11 (as additional challenges), but these
extra steps never produced vasospasm. Step 11, used only in
the two ovx monkeys in which vasospasm was not found by this
point, was the triple combination (in 1 ml) of 100 mmol/liter
serotonin and 1 mmol/liter U46619 with 1 nmol/liter ET1,
which also did not produce vasospasm. Step 12 was a Ca21
antagonist, either nitrendipine or mibefradil, as a vasodilator
to relieve the vasospasm or cardiogenic shock that was the end
point for step 11.
A separate mechanical injury protocol 2 (Table 2) was used
in three additional monkeys (one male, two ovx). The injury
step of protocol 2 was deliberate mechanical stretching of the
LAD or left main coronary artery with a 5F catheter. (Except
in these three monkeys with deliberate mechanical injury, the
other seven [protocol 1] monkeys were studied with 3F cathe-
ters only to avoid mechanical injury, as verified by 1) lack of
constriction at the catheter tip, 2) no occlusion of coronary
flow by the catheter, and 3) no evidence of injury on dissection
and histopathologic examination, as described later).
Recovery and pathologic studies. Maximal experiment du-
ration was #3 h. After the protocols, catheters and electrocar-
diographic electrodes were removed, and incisions were surgi-
cally closed. Isoflurane anesthesia was discontinued, the
endotracheal tube was removed, and sedation was maintained
using ketamine (15 mg/kg intramuscularly) until euthanasia in
the necropsy room. Monkeys were euthanized by an overdose
of intravenous Na1 pentobarbital and exsanguination. Hearts
were examined in situ for abnormalities in size and shape,
removed and immediately dissected. The aorta and opened
coronary arteries were further evaluated for narrowing, thick-
ening or thrombosis, and myocardial slices were examined for
color changes suggestive of lesions. Cross-sectional blocks of
aorta and coronary arteries with adjacent myocardium were
processed for glycol methacrylate embedding, and 2-mm sec-
tions were evaluated using hematoxylin-Lee, giemsa and Ver-
hoeff stains.
Concentrations of drugs in coronary blood. Effective auta-
coid concentration (as diluted by blood flow) at the VMC
membrane is critical but elusive. We based the analysis in
Table 3 on the following assumptions. All injections were 1 ml,
infused by hand steadily over a 30-s interval. The concentra-
tions in the syringe would have been diluted instantaneously by
coronary blood flow. Based on size, the 3F (1.0-mm outer
diameter) catheter (area 0.785 mm2) would occlude coronary
blood flow in the average 1.35-mm diameter coronary artery
(area 1.43 mm2) by 54% (under the preconstriction condi-
tions). With coronary blood flow of 30 ml/min in this case, the
concentration reaching a VMC would therefore be diluted
about 15 times or more with distance from the injection point.
Table 1. Protocol 1: Drug-Induced Protocol for
Coronary Vasospasm*
1. IC injection of contrast media to establish arterial diameters before drugs
(control)
2. IC injection of 100 nmol/liter (0.018 mg) acetylcholine to show dilator
capacity
3. IC injection of 1 mmol/liter acetylcholine (0.18 mg) to show dilator
capacity
4. IC injection of 100 mmol/liter (17.6 mg) serotonin
5. IC injection of 1 mmol/liter (176 mg) serotonin
6. IC injection of 100 nmol/liter (0.035 mg) U46619 (stable thromboxane A2
mimetic)
7. IC injection of 1 mmol/liter (0.35 mg) U46619
8. Challenge 1 with combined 100 mmol/liter (17.6 mg) serotonin and 1
mmol/liter (0.35 mg) U46619
9. Challenge 2 with combined serotonin–U46619 stimulation
10. Challenge 3 with combined serotonin–U46619 stimulation
11. Triple combination with serotonin and U46619 and 1 nmol/liter
endothelin 1 or serotonin and U46619 and mmol/liter angiotensin II
12. Dilation 15 min later with 1 or 10 mmol/liter nitrendipine or Ro 40-5967
(mibefradil)
*All concentrations are expressed as the undiluted solution in the injection
syringe, but would have been diluted 15 times by coronary blood flow as the 1 ml
was injected over 30 s. Coronary blood flow under these conditions was estimated
at 30 ml/min (allowing for 50% flow obstruction by the catheter), as explained in
Methods. This protocol was used in seven ovariectomized rhesus monkeys. IC 5
intracoronary.
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However, the blood flow through individual epicardial arteries
(LAD or left circumflex) would have represented only part of
total coronary flow, offsetting the downstream dilution. We
compromised on the factor of 15 times for the Table 3
concentrations, although we acknowledge that this is only an
approximation.
Coronary artery diameter measurement. Putative coro-
nary vasospasm stimuli were judged primarily by actions on
large coronary artery diameters, analyzed as diameter of the
most proximal focus of vasospasm at end-diastole from video-
taped images recorded at 30 frames/s. We used the image
analysis program Image Pro to measure the diameters from
single frames acquired with an Imagraph frame grabber in a
Pentium computer. We used the 3F catheter tip ring (1.0 mm)
for calibration and determined minimal and maximal diame-
ters just distal to the constriction. All responses to interven-
tions were also X-ray imaged immediately (15 to 30 s after
injection) and at exactly 3 min (and 15 min if there was
vasospasm) after injection. Interobserver variability (coeffi-
cient of variation) was 7% on repeat measurements, as tested
on selected samples.
Statistical analysis. Results are expressed as mean value6
SEM for all variables measured. Statistical significance was
determined by analysis of variance with Bonferroni protected
paired t tests. Values of p #0.05 were accepted as significant.
Results
Protocols that failed to induce coronary vasospasm. Single-
drug challenges. Coronary catheterization laboratory studies of
vasoconstriction in male or ovx rhesus monkeys were begun by
individually testing serotonin, TxA2 mimetic (U46619), ET1 or
AII by injection in increasing (half-log units) concentrations to
find the reduction of artery diameter by 50%. We used 10
times as the multiplier (where practical) to reach the maximal
dose to be tried (Table 3). No vasoconstrictor alone caused
coronary vasospasm, even though there were transient reduc-
tions to 20% of control diameter. The first injection in protocol
1 was a low dose of 6.7 nmol/liter ACh to test endothelial
integrity, as judged by vasodilation, which was sufficient in
sensitive arteries (three females, one male), whereas 67 nmol/
liter ACh produced immediate vasodilation within 15 s in all
monkeys.
Intracoronary injections of serotonin from 67 nmol/liter to
667 mmol/liter were vasoactive in all animals. The 6.7 mmol/
liter concentration (step 4 in the protocol) caused dilation of
the larger arteries (in 4 of 10), whereas 67 mmol/liter (step 5)
produced variable vasoconstriction of large arteries (mild
constriction in 5, but no change in 5), and small arteries in all
10, indicated by increased time to clear radiocontrast media.
Table 2. Protocol 2: Mechanical Injury Protocol for
Coronary Vasospasm*
1. IC injection of contrast media to establish arterial diameters before drugs
(control)
2. IC injection of 100 nmol/liter (0.018 mg) acetylcholine to show dilator
capacity
3. IC injection of 1 mmol/liter (0.18 mg) acetylcholine to show dilator
capacity
4. IC injection of 100 mmol/liter (17.6 mg) serotonin
5. IC injection of 1 mmol/liter (176 mg) serotonin
6. IC injection of endothelin-1 (sequential doses to 10 nmol/liter)
7. IC injection of angiotensin II (sequential doses to 10 mmol/liter)
8. Injury by stretching the coronary artery with a 5F catheter
9. IC injection of serotonin (sequential doses to 1 mmol/liter)
10. IC injection 15 min later with 1 or 10 mmol/liter nitrendipine or Ro 40-
5967 (mibefradil)
11. IC injection of U46619 (sequential doses to 10 mmol/liter)
12. IC injection 15 min later with 1 or 10 mmol/liter nitrendipine or Ro 40-
5967
*This protocol was used in three rhesus monkeys. IC 5 intracoronary.
Table 3. Sensitivity to Vasospasm Stimuli
ED50
(2log mol/liter)
EC50
(2log mol/liter)
Max Dose
(2log mol/liter) Spasms/N Protocol
Single stimulus
Serotonin* 2.5 3.8 2 0/8 1†
U46619 5.5 6.8 5 0/8 1†
Endothelin 1 8.5 9.8 8 0/3 2
Angiotensin II 5.5 6.8 5 0/3 2
Combined stimuli
Endothelin 11serotonin‡ 9 10.3 8 0/3 2
Angiotensin II1serotonin‡ 6 7.3 5 0/3 2
Mechanical injury1serotonin‡ NA NA NA 3/3 2
U466191serotonin‡ 6 7.3 5 5/7 1
*1 mmol/liter. †One of the protocol 2 animals also was tested with serotonin alone and U46619 alone, after the
angiotensin II step, accounting for the total of eight in the first two rows. Vasospasms all consisted of reduction to #25%
of control diameter with downstream dilation (hourglass shape) that persisted for $15 min. ‡100 mmol/liter. EC50 5
estimated actual coronary artery blood concentration in 2log mol/liter based on a 15-fold dilution, (for details, see
Methods); ED50 5 dose in mmol/liter (as the concentration in the syringe, without allowing for any dilution due to
coronary blood flow) of the named vasoconstrictor that caused a 50% reduction of diameter from control; Max Dose 5
maximal dose tried (syringe concentration) in 2log mol/liter for each vasoconstrictor; N 5 number of animals in a
protocol; NA 5 not applicable; Spasms 5 number of animals with vasospasm.
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These serotonin-induced contractions appeared uniform along
the length of the arteries, with no evidence of the characteristic
vasospasm hourglass profile. Estimated EC50 concentrations
(allowing for 15 times dilution of syringe concentrations) for
50% diameter reduction (EC50) was 200 mmol/liter (Table 3).
Intracoronary injection of the stable TxA2 mimetic U46619
in concentrations from 6.7 to 2,000 nmol/liter caused constric-
tion of arteries in all 10 monkeys, predominantly due to
constriction of small arteries and markedly increased total
coronary resistance as indicated by fluoroscopy (resistance to
injection and slow clearance of the radioopaque contrast
media). Thromboxane A2 at 6.7 nmol/liter (step 6) substan-
tially reduced intramural small-vessel diameter and impaired
cardiac contractility (decreased maximum rate of increase in
pulse [dP/dt]). As opposed to injections of serotonin, which
characteristically increased heart rate and blood pressure,
TxA2 injections increased blood pressure with decreased or
unchanged heart rate. At 67 nmol/liter, TxA2 caused vasocon-
striction of predominantly small-resistance arteries, evidenced
by pronounced ischemic narrowing, decreases in blood pres-
sure and increased time to clear radiocontrast media in all
monkeys (step 7). The estimated EC50 for 50% diameter
reduction was 200 nmol/liter (Table 3). Although blood pres-
sure and cardiac contractility decreased with repeat injections
of high TxA2 doses, there was no coronary vasospasm with
TxA2 alone.
Endothelin 1 alone or with serotonin. Endothelin 1 in con-
centrations up to 2 nmol/liter did not cause vasospasm. Cardiac
systolic function was depressed (decreased dP/dt), and there
were 50% reductions in diameter of only two arteries to ET1
plus serotonin, but there was no coronary vasospasm. Addition
of 6.7 mmol/liter serotonin increased sensitivity by three times;
the estimated ET1 EC50 of the responsive ovx monkeys was
200 pmol/liter without and 67 pmol/liter with serotonin (Table
3). The triple combination with 67 nmol/liter U46619, used in
the two ovx monkeys that failed to show vasospasm by this
point, produced cardiogenic shock but not vasospasm; diastolic
blood pressure fell to #20 mm Hg, and the heart was severely
hypokinetic as observed by fluoroscopy.
Angiotensin II alone or with serotonin. Angiotensin II in
concentrations up to 200 nmol/liter did not cause vasospasm
but did increase systemic blood pressure. Coronary diameters
were not obviously affected, except in one ovx monkey, from
which a maximal sensitivity of 200 nmol/liter without and 67
nmol/liter with serotonin was estimated (Table 3). Although
the combination with serotonin increased heart rate, there was
no coronary vasospasm (Table 3).
Protocols that induced coronary vasospasm. Mechanical
injury. As a basis for comparison, we used deliberate injury to
the coronary arteries inflicted by stretching with a catheter with
deliberately roughened tip, in one male and two ovx monkeys
(protocol 2, Table 2). The stretch maneuver would cause injury
to both endothelium and media and induce local vasoconstric-
tion. Intracoronary injection of 67 mmol/liter serotonin subse-
quent to injury caused coronary vasospasm at multiple sites, as
demonstrated in the male monkey (Fig. 1). Before injury,
arteries were open and well filled (Fig. 1A). The 5F catheter
was then advanced to produce injury by a single stretch at the
point marked by the radioopaque tip, which produced tran-
sient focal narrowing to 20% of control, with recovery to
.50% in 4 min. We injected 67 mmol/liter serotonin (IC)
12 min later as 1 ml over 30 s (as explained in Methods),
causing vasospasm evident at three focal points made promi-
nent by three distal dilations (Fig. 1B) forming the classical
hourglass pattern that mimics human coronary vasospasm.
Vasospasm was relieved with injection of 10 mmol/liter nitren-
dipine (no dilution allowed for in this low blood flow condi-
tion), as shown by return to nearly control dimensions (except
at the injury region near the catheter tip) in Figure 1C.
Subsequent injection of 67 nmol/liter U46619 caused another
vasospasm with the same foci as that for serotonin (Fig. 1D).
Even in the deliberate catheter injury experiment shown in
Figure 1, the vasospasm induced was not simply a local
response to direct mechanical injury because vasospasm oc-
curred not only at the point of artery wall injury, but also at foci
several millimeters distal to the injury. Such characteristic focal
contractions appeared at least 10 to 25 mm beyond the furthest
point ever reached by guide wires or catheters. Focal constric-
tion and downstream dilation occurred that would be consis-
tent with punctate release or sites of hyperreactivity, or both,
because there was no evidence of emboli.
The injury in Figure 1 was imposed with a 5F catheter that
stretched the left main coronary artery. Vasospasm was stim-
ulated by subsequent IC serotonin or 1 nmol/liter U46619 but
not by #10 nmol/liter ET1 or #10 mmol/liter AII. With 4F
catheters, there was also injury due to stretching and flow
occlusion in these 25- to 45-g hearts. Mechanical injury was
also used in two ovx monkeys (protocol 2), with multiple
vasospasms similar to the results in the male monkey shown in
Figure 1. However, in the remaining seven ovx monkeys, only
3F catheters along with protocol 1 were used to avoid injury to
study purely drug-induced coronary vasospasm.
Combined serotonin and TxA2 . With the combination of 6.7
mmol/liter serotonin and 67 nmol/liter U46619, we found
coronary vasospasm in five of seven ovx monkeys, even though
vasospasm could not be found in response to 6.7 or 200
mmol/liter serotonin alone or 6.7 to 2,000 nmol/liter U46619
alone in the same seven animals (Table 3). None of the seven
monkeys responded to the first serotonin and U46619 combi-
nation injection; two responded to the second injection; and 3
responded to the third injection with vasospasm. The two that
did not show vasospasm nevertheless showed severe vasocon-
striction and are included in the hemodynamic data in Table 4.
Sample angiograms showing vasospasm induced by the combi-
nation of serotonin and U46619 are displayed in Figure 2. The
control condition (Fig. 2A) shows a normally patent left main
coronary artery filled with radioopaque contrast media. Con-
striction 15 s after the second injection of serotonin and
U46619 is shown in Figure 2B and after 3 min in Figure 2C. All
vasospasms observed in protocol 1 occurred .5 mm beyond
the most distal point ever reached by either catheter or guide
wire.
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The onset of constriction to the serotonin and U46619
combination injection began immediately on arrival and was
evident on the first film (15 s after the injection). The
contraction progressed over the next 2 min, reaching a peak
between 2 and 4 min from the end of injection. The number of
vasospasm regions in a major artery averaged three (range one
to six). When there was more than one vasospasm in an artery,
the second and subsequent vasospasms occurred 5 to 25 mm
distal to the first focal vasospasm. The hourglass pattern in
Figure 2C is similar to that in the mechanical injury plus
serotonin vasospasm (Fig. 1, B and D).
Life-threatening reductions in blood pressure and cardiac
contractility resulted from such severe coronary ischemia
(Table 4). Diastolic blood pressure fell to ,20 mm Hg in
several monkeys, correlated with more than fivefold decreases
in dP/dt values (cardiac contractility) and faint ventricular
contractions observed fluoroscopically. Systolic blood pressure
correspondingly fell to ,40 mm Hg, and in several cases heart
rate fell to ,60 beats/min. Minimal diameter was severely
reduced, in some loci to ,0.1 mm (,8%), and downstream
dilation was more than five times the diameter at the vaso-
spasm focus. All variables except maximal diameter were
significantly different from control values, as indicated by
daggers in Table 4.
Relief of coronary vasospasm. To allow monkeys to recover
and prevent death due to cardiogenic shock, we followed
combined serotonin and U46619 stimulation with an IC Ca21
antagonist, either nitrendipine or mibefradil, at the end of the
15-min vasospasm, except for that in Figure 2. Intracoronary
injection of 1 ml of 10 mmol/liter nitrendipine or 1 mmol/liter
mibefradil (without allowing for dilution due to severely
reduced blood flow) caused improved cardiac performance,
beginning ;1 to 3 min after injection, with an increase in
systolic and diastolic blood pressure and improved cardiac
contractility (increased dP/dt). In monkeys with severe vaso-
constriction and low heart rates (,90 beats/ min), Ca21
antagonists effected increases to 90 to 200 beats/min due to
reversal of atrioventricular conduction blocks (evident in the
recovery of heart rate shown in Table 4). Hemodynamic
variables returned to levels not significantly different from
control with the help of Ca21 antagonists, although there was
a trend toward increased heart rate.
Nitrendipine (1 to 10 mmol/liter not allowing for dilution)
injected IC was effective in eliminating the vasospasm, even in
animals that had diastolic blood pressures as low as 20 mm Hg.
Mibefradil (Ro 40-5967) IC injections at 0.1 to 10 mmol/liter
(without allowing for any dilution by blood flow) were also
immediately effective in relieving vasospasm and returning
blood pressures from diastolic levels as low as 10 to 20 mm Hg
back to normal ranges (minimums of 100/60 mm Hg for
systolic/diastolic levels). Figure 3 shows an experiment in which
vasospasm was induced by serotonin and U46619 combination
injection and relieved by Ca21 antagonist. Figure 3A is the
control circulation, which contrasts with early vasospasm in
Figure 3B (at 15 s) and the fully developed vasospasm in
Figure 3C. Relief of the vasospasm is shown in Figure 3D and
by hemodynamic variables in Table 4. In all monkeys, Ca21
antagonists relieved vasospasm, allowing recovery of blood
pressures, heart rate and contractility toward normal.
Pathologic examinations. Gross structural abnormalities
were not seen in any of the hearts. There was also no visible
evidence of acute injury or preexisting lesions in coronary
arteries or the myocardium at or near the spasm foci. Multiple
small fibrous plaques were present in the aortas of two animals
(the 18-year old ovx monkey in Fig. 3 and another 13-year old
ovx monkey), which both showed vasospasm. However, the
lesions were minor, confined to the aortic arch and would not
Figure 1. Injury-induced coronary vasospasms with focal constrictions
and downstream dilations (hourglass pattern) are shown in the left
circumflex coronary artery of a 14-year old male rhesus monkey. The
control angiogram (A) shows well dilated coronary arteries before
injury. After injury by stretching with the 5F catheter (the injured
region extends to the radioopaque tip of the catheter) and infusion of
1 ml of 1 mmol/liter serotonin over a 30-s interval (67 mmol/liter after
dilution), there was vasospastic constriction, with branches and smaller
coronary arteries disappearing from the image (B). Arrows mark two
sites of vasospasm .5 mm beyond the farthest extent of stretching.
After infusion of 1 ml of 10 mmol/liter nitrendipine (not assuming any
dilution because of the ischemia) over a 30-s interval, there was relief
of vasospasm and an increase in the diameter of the artery (C).
Injection of 1 mmol/liter U46619 (estimated to be 67 nmol/liter after
dilution) caused redevelopment of constriction and vasospasm at the
same focal areas (arrows) (D).
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have influenced the vasospasms reported here. The same
monkey showed a small microscopic focus of intimal thicken-
ing in an apical portion of the LAD, and there was segmentally
denuded endothelium in one small area in this and one other
13-year old ovx monkey that did not show vasospasm. There
were small thrombi composed of fibrin and platelets in only
this one monkey with vasospasm. The 18-year old ovx monkey
in Figure 2, which was the only monkey in this series that died
as the result of vasospasm, showed acute cytolytic changes
consisting of wavy fibers and sarcoplasmic vacuolation accom-
panied by interstitial edema in the left ventricle, probably as a
result of the fatal vasospasm.
Discussion
These results show that even in the absence of injury or
plaques, stimulation by the combination of serotonin and a
mimetic of TxA2 evokes coronary vasospasm in ovx rhesus
monkeys. The radiologic appearance and pharmacologic re-
sponses closely mimic characteristics of human coronary vaso-
spasm found in diagnostic provocative testing with single
injections of ergonovine, histamine or high dose ACh
(12,14,16,19,29–32). The lack of epicardial vasospasm in re-
sponse to single agonists is remarkable and probably accounts
for the difficulty in provoking vasospasm in animals. The
requirement for a combination of synergistic stimuli would
suggest that the vasospasm phenomenon is complex. These
results support the hyperreactivity hypothesis for vasospasm
that had been deduced earlier from observations of human
angiograms (5,17) and demonstrate a useful animal model of
human vasospasm.
Comparison with human vasospasm. Based on initiating
stimulus, characteristic hourglass pattern of focal constriction
followed by downstream dilation, extended time course of
profound vasoconstriction and pharmacology of vasospasm
reversal, this rhesus monkey coronary vasospasm model closely
mimics human coronary vasospasm. The serotonin and
U46619 combination stimulus caused a similar pattern of vaso-
spasm to that found in human patients (1,2,6,13) or caused by
mechanical injury (with the catheter tip), as shown by compar-
ison of Figure 1 with Figures 2 and 3. Vasospasm (as defined
here) required stimulation by serotonin, even after mechanical
injury, in all monkeys studied. The requirement for a vasocon-
strictor in both drug-induced and mechanical protocols em-
phasizes the importance of blood vessel reactivity. Hyperreac-
tivity, whether due to endothelial denudation, appears to be an
Figure 2. Drug-induced vasospasm is shown by angiograms from an
18-year old ovx monkey right coronary artery (without injury). Multi-
ple vasospastic hourglass patterns formed in response to the second
challenge with the combination serotonin-TxA2 provocation. The
control condition is shown in A. After the second injection of the
combination of 6.7 mmol/liter serotonin and 67 nmol/liter U46619,
after an identical first challenge by 10 min, loci of constrictions began
to form, evident as decreases in diameter interspersed among regions
of almost normal diameter, as shown here at 30 s (B). These regions
already identified where spasms would occur at 5 min, at which time
diameters were ,25% of control at the points indicated by five arrows
(C). This was the only monkey in this study group that did not survive
vasospasm. In this case, recovery by direct myocardial stimulation was
unsuccessfully attempted with 1 ml of 100 mmol/liter epinephrine (not
allowing for dilution) injected IC over 30 s (instead of vasodilation by
a Ca21 antagonist).
Table 4. Hemodynamic Variable Changes at Control, Serotonin and
U46619 Combination and Recovery Steps in Drug-Induced
Vasospasm Protocol in Seven Ovariectomized Rhesus Monkeys*
Control
(mean 6 SEM)
S1U
(mean 6 SEM)
Recovery
(mean 6 SEM)†
Systolic BP (mm Hg) 1226 7 83 6 14‡ 114 6 10
Diastolic BP (mm Hg) 846 6 43 6 15‡ 76 6 11
dP/dt max 1,6536 437 305 6 136‡ 1,285 6 548
Heart rate (beats/min) 1076 5 74 6 18‡ 126 6 22
Min diameter (mm) 1.336 0.45 0.22 6 0.11‡ 1.08 6 0.76
Max diameter (mm) 1.356 0.44 1.12 6 0.68 1.21 6 0.77
*All seven monkeys without mechanical injury are included in these data,
whether showing vasospasm (5 monkeys) or not (2 monkeys). The three monkeys
that received mechanical injury are excluded from the table. †The monkey that
did not recover (Fig. 2) is not included in these data. ‡All serotonin and U46619
combination data except maximal diameter are significantly different from
control and recovery data by Bonferroni protected t tests (p, 0.05). BP5 blood
pressure; diameter 5 point of greatest vasoconstriction (Min) and downstream
dilation (Max) (in mm) before, during the peak of the serotonin and U46619
combination vasospasm and after recovery; dP/dt max 5 maximal rate of
increase of left ventricular blood pressure measured from the intraarterial blood
pressure catheter in mm Hg/s.
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important component in the etiology (5,17) and is a logical
deduction from the hourglass shaped constriction, although
this point has been vigorously debated (2).
Platelet release substances provoke vasospasm. The re-
sults add to growing support for the hyperreactivity hypothesis
that spontaneously occurring functional vasospasm is closely
associated with sensitivity to stimulation by the combination of
serotonin and TxA2. Similar serotonin–thromboxane correla-
tions have been made in patients and were suggested to pro-
vide an important pathophysiologic mechanism (4,7,12,14,33).
Our findings are consistent with those from human angio-
plasty, in which serotonergic receptor stimulation was essen-
tial, as shown by block with serotonin antagonists (e.g., methy-
sergide or LY 53587) (9,19,20,34).
The concentrations of serotonin used here are similar to
those for serotonergic agonists used to provoke vasospasm in
patients but are much higher than circulating levels measured
in the coronary sinus (32,35). However, platelet volume is
extremely small, and the release of products is local; thus,
release site/circulating ratios .106 times would be anticipated.
The 5 ng/ml of serotonin measured in flow-diluted coronary
sinus blood (12,32) could thus represent up to 5 mmol/liter
released in the vicinity of the activated platelet. If so, concen-
trations injected in the present studies would represent similar
conditions to platelet local release. The injections here ex-
posed coronary arteries to an estimated concentration of 67
mmol/liter serotonin (see Methods) for 30 s, which may even be
only a fraction of stimulus duration when released by platelets.
Our IC injection would have been immediately washed out by
blood flow instead of being anchored to a site, as a thrombus
would have been. Immediate washout offers a plausible expla-
nation for the requirement for simultaneous stimuli to trigger
drug-induced vasospasm. Serotonin amplified responses to
U46619 and other vasoconstrictors, causing a 1⁄2 log unit lower
EC50 in each instance (Table 3).
Vasospasm due to increased reactivity. To our knowledge,
we demonstrated for the first time in an animal that vasospasm
can be drug induced, even without stenosis or atherogenic
diets, which are known to increase coronary reactivity
(23,25,36–38). The hypothesis is thus supported (i.e., throm-
boxane A2 supersensitivity of VMC causes vasospasm in the
setting of concomitant serotonin). The combination of local
platelet release of TxA2 and serotonin with supersensitivity
(28) of small groups of VMC can explain focal contraction
areas, perhaps implicating increased TxA2 receptor numbers,
as reported in myocardial infarction and unstable angina
pectoris (39). With both protocols, monkey coronary vaso-
spasm had the same familiar hourglass pattern as in human
patients (Figs. 1 to 3).
Virtues and limitations of primate model. Vasoconstrictor
stimulation allows the purely functional aspect of vasospasm to
be separated from structural mechanisms. This simplification
of the vasospasm process would be unlikely, or at least
extremely difficult, in humans, where lack of atherosclerotic
plaques is rare (2,33). Rhesus monkeys in which hormonal
status, diet and medical history are defined and controlled
allow a rare and definitive test of specific mechanisms for
induction of functional (rather than structural) coronary vaso-
spasm. Unlike other models, the ovx rhesus monkeys required
no crush or other injury or restriction of coronary arteries.
There is no chance of smoking, stress, lipids or other compli-
cations of human vasospasm, and heart disease is rare in rhesus
macaques (25,36). A hypoestrogenic state was a necessary
factor for hyperreactivity sufficient to allow vasospasm to exist
because vasospasm was not found with a similar protocol in
monkeys that had physiologic levels of estrogen and proges-
terone (40). However, we recognize that there may be un-
Figure 3. Drug-induced coronary vasospasm (in uninjured coronary
arteries of an 18-year old ovx monkey) and relief by the Ca21
antagonist mibefradil (Ro 40-5967) are shown by this series of
angiograms. Control left circumflex and LAD coronary arteries are
shown in A. Regions of strong constriction began 15 s after stimulation
with the second challenge (7 min after an identical first challenge) with
serotonin and U46619 combination, as shown in B. Focal constrictions
followed by dilations (vasospasms) are demonstrated at 3 min in C.
Several sites showed reductions of 90% compared with control diam-
eter, as indicated by the four arrows. Relief of vasospasm by
10 mmol/liter mibefradil (no dilution assumed because of marked-
ly reduced blood flow) is shown in D. IC injection of mibefradil
reversed vasospasm and returned blood pressure, which had dropped
,40/20 mm Hg, to .100/60 mm Hg due to improved cardiac function
(observed fluoroscopically as improved contraction strength and more
rapid radiocontrast medium clearance).
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known differences in coronary artery characteristics between
rhesus monkeys and humans that could limit the extrapolation
of this hyperreactivity mechanism. Injection of combined se-
rotonin and U46619 produced small-artery constriction greater
than might occur in variant vasospasm. However, rhesus
monkey coronary arteries appear more relevant to human
coronary arteries than those of other animals (e.g., pig, dog,
rabbit or pigeon) in appearance and dynamics of vasospasm
(18) and appear to be particularly useful for comparative study
of mechanisms hypothesized to underlie functional vasospasm
(2,7,10,14,20).
Questions raised. These data support the reports that
platelet release products are important in the etiology of
coronary vasospasm (7,8,41) and thus support the thrombus
vasoconstrictor release/hyperreactivity hypothesis. There can
be little doubt that platelet aggregation is intimately involved
in vasospasm based on success of the monoclonal antibody 7E3
against glycoprotein IIb/IIIa receptor, effectively blocking
platelet aggregation and relieving vasospasm in patients (42).
Platelet Ca21 vasoconstrictor abnormalities are also thought to
contribute to the increased risk of vasospasm in hypertension
(43). Because thrombus formation and dissolution of plaques
is a dynamic process (9), spasm occurrence may be determined
by sensitivity of VMC to vasoconstrictor release. There remain
several fundamental questions. Is the site of vasospasm defined
by a localized increase in vasoconstrictor sensitivity? Which
changes in platelets are necessary for triggering the vaso-
spasm? Although these and other puzzles remain to be solved,
we conclude that vasospastic (structure independent) vaso-
spasm can be stimulated in hyperreactive coronary arteries by
combined platelet release products.
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